Harvard Bioscience, Inc. (HBIO) Fair Value 2026

HBIO · Medical Instruments & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.8 /10

32 fundamental signals · 5 models active

Value Trap Risk

LOW (30/100)

Quick Summary — As of 2026-08-28, Harvard Bioscience, Inc. (HBIO) trades at $7.93, versus a $14.84 median fair value across its 5 active models — 87.2% above the current price. QOC: 5.8/10. Value Trap Risk: 30/100 (LOW). 5/13 models active.

Key Facts

Ticker
HBIO
Price
$7.93
Quality Score
5.8/10
Value Trap Risk
30/100
Models Active
5/13
Last Updated
Strength: CUCE Ensemble suggests +87.2% upside with 21% confidence
Risk: Limited model coverage (5/13) may reduce confidence

Is Harvard Bioscience, Inc. (HBIO) Undervalued or Overvalued in 2026?

According to CirclFi’s 5-model valuation engine, Harvard Bioscience, Inc. (HBIO) appears undervalued as of : the median of 5 independent fair value estimates is $14.84, 87.2% above the current price of $7.93. Estimates range from $10.20 to $22.83. HBIO scores 5.8/10 on fundamental quality and 30/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. HBIO’s +87.2% gap is wider than that market norm, and the Medical Instruments & Supplies sector median is -29.3%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Harvard Bioscience, Inc. Stock in 2026? →

What Fair Value Does Each Model Give HBIO?

5 Intrinsic Value Models vs. Current Price ($7.93)

Core Models (Unlocked)
Model Fair Value Upside
Ensemble · Medium Conviction
 $14.84 +87.2%
Intrinsic · High Conviction
 $11.23 +41.6%
Unlock the Full Matrix

Access 3 additional models including PWERM, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 5 Models →

Cancel anytime · No contracts · Instant access

What Is HBIO's Fair Value Range?

Spread across 5 independent models · $10.20 to $22.83

CirclFi's 5 active models place Harvard Bioscience, Inc. (HBIO) between $10.20 and $22.83 per share, a spread of 85% of the median. The median of that range — $14.84 — is the fair value CirclFi publishes for HBIO, against a current price of $7.93.

Low · PWERMHigh · Regime Cross
$10.20median $14.84$22.83
Where the range comes from
Most bearish modelPWERM$10.20
Most bullish modelRegime Cross-Sectional$22.83
Model agreement5 bullish · 0 bearishmoderate

A band of this width is typical. The methods agree on direction but weight growth, reinvestment and risk differently, so treat the median as a centre of gravity rather than a precise target.

Every figure above is one model's standalone output on HBIO, not a CirclFi price target. How each model works →

What Is Harvard Bioscience, Inc. (HBIO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Harvard Bioscience, Inc. is potentially undervalued at its current price of $7.93. Based on our 13-model framework, Harvard Bioscience, Inc.'s intrinsic value is estimated at a median fair value of $14.84 — representing +87.2% implied upside — with 5 out of 5 active models confirming this thesis. Model dispersion is worth noting: Regime Cross targets $22.83 (+187.9%), versus PWERM at $10.20 (+28.6%). This +159.3% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About HBIO?

5 of 13 models are currently active for HBIO. All 5 active models suggest the stock trades below fair value. Taken together, their median fair value for HBIO is $14.84 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does HBIO Rank in Medical Instruments & Supplies?

Among 56 Medical Instruments & Supplies stocks, HBIO ranks #42 by Quality of Company score. CirclFi's QOC score of 5.8/10 evaluates 32 fundamental signals. A score of 5.8 reflects mixed fundamentals.

See all Most Undervalued Medical Instruments & Supplies Stocks →

Harvard Bioscience, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is HBIO a Value Trap?

CirclFi's Value Trap algorithm assigns HBIO a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

5 of 13 models are active for Harvard Bioscience, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Harvard Bioscience, Inc. earns a quality score of 5.8/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +159.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HBIO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across HBIO's 5 active models, average confidence is 34%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Harvard Bioscience, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Instruments & Supplies Stocks Should You Also Analyze?

11 related Medical Instruments & Supplies stocks with 13-model coverage

BNGOBionano Genomics, Inc.QOC 5.8CUPRCuprina Holdings (Cayman) LimitedQOC 5.6KMTSKestra Medical Technologies, Ltd.QOC 5.8NYXHNyxoah SAQOC 5.6STXSStereotaxis, Inc.QOC 6.1LUCYLucyd, IncQOC 5.6NNNNAnbio BiotechnologyQOC 2.4EMBCEmbecta Corp.QOC 7.8ANGOAngioDynamics, Inc.QOC 6.7ISRGIntuitive Surgical, Inc.QOC 9.4RMDResMed Inc.QOC 9.4

Read investment analysis: BNGO · CUPR · KMTS · NYXH · STXS · LUCY · NNNN · EMBC · ANGO · ISRG · RMD

Which Other Stocks Have a Similar Quality Score to HBIO?

7 companies across all industries closest to HBIO’s Quality of Company score of 5.8/10.

ATAIAtaiBeckley Inc.QOC 5.8CCOICogent Communications Holdings, Inc.QOC 5.8LUMNLumen Technologies, Inc.QOC 5.8SUNCSunocoCorp LLCQOC 5.8PRSOPeraso Inc.QOC 5.8AIFAAll In FutureTech Alliance Inc.QOC 5.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ATAI · CCOI · LUMN · SUNC · PRSO · AIFA · NVDA

Where Does HBIO Sit in CirclFi's Medical Instruments & Supplies Rankings?

HBIO is ranked against every other Medical Instruments & Supplies stock CirclFi covers in each of these screens.

See all Medical Instruments & Supplies stocks ranked →

What Else Do Investors Ask About Harvard Bioscience, Inc.’s Valuation?

What is Harvard Bioscience, Inc.'s intrinsic value in 2026?

CirclFi puts Harvard Bioscience, Inc. (HBIO)'s intrinsic value at $14.84 — the median of 5 independent model estimates as of 2026-08-28, ranging from $10.20 to $22.83. The Quality of Company score is 5.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HBIO overvalued or undervalued right now?

At $7.93, 5 of 5 active models suggest HBIO may be undervalued, while 0 indicate potential overvaluation. The median of all 5 fair value estimates is $14.84, 87.2% above the current price of $7.93 — a consensus view that HBIO is undervalued. The assessment depends on which methodology best fits Harvard Bioscience, Inc.'s business model in Medical Instruments & Supplies.

What does a Quality of Company score of 5.8 mean for HBIO?

Harvard Bioscience, Inc.'s QOC of 5.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on HBIO?

CirclFi analyzes HBIO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 5 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on HBIO?

Of the 5 models currently active on HBIO, Regime Cross-Sectional is the most bullish at $22.83 per share, and PWERM is the most bearish at $10.20. CirclFi's published fair value for HBIO is the median of that range, $14.84, not either extreme. The gap between the two ends equals 85% of the median — a normal spread for a company of this profile. Browse stocks by value-trap risk →

Is HBIO a value trap in 2026?

Harvard Bioscience, Inc.'s Value Trap score is 30/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 5-model valuation engine, Harvard Bioscience, Inc. (HBIO) has a median fair value of $14.84 — 87.2% above the current price of $7.93 — as of 2026-08-28.” Source: circlfi.com/stock/HBIO/ · Methodology
Primary sources for this HBIO valuation
  • Financial statements: Harvard Bioscience, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001123494) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for HBIO as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 5 mathematical frameworks give you clarity on HBIO.

Unlock All 5 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for HBIO Unlock All 5 — $39/mo